Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Myeloid 2Head & Neck 2CNS 2Thoracic 1Sarcoma 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Glioblastoma 157Brain Neoplasms 98Glioma 69Gliosarcoma 43Astrocytoma 30Carcinoma, Non-Small-Cell Lung 19Recurrence 18Oligodendroglioma 18Central Nervous System Neoplasms 16Neoplasms 14Meningeal Carcinomatosis 10Ependymoma 10Meningioma 7Neurofibromatosis 2 6Neuroblastoma 6Melanoma 6Diffuse Intrinsic Pontine Glioma 6Neuroma, Acoustic 5Medulloblastoma 5Lung Neoplasms 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neurologic Manifestations 4Colorectal Neoplasms 4Breast Neoplasms 4Spinal Cord Neoplasms 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3

Interventions

Nivolumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3pembrolizumab 2Fluorodeoxyglucose F18 2FAPI-46 2Bevacizumab 2temsirolimus 1regorafenib 1aflibercept 1X-Rays 1Valproic Acid 1Specimen Handling 1Sirolimus 1Paclitaxel 1NEO212 1Immunoglobulin G 1IFL protocol 1Disulfides 1Cetuximab 1Carboplatin 1CTLA-4 Antigen 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Bevacizumab × CNS × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡